In a nutshell This study investigated if nivolumab (Opdivo) is safe and effective in patients with rare melanoma subtypes (RMS) who progressed after ipilimumab (Yervoy). They found that this treatment was safe and improved survival in certain RMS. Some background Melanoma the most common cancers. There are many subtypes...
Read MoreIn a nutshell This study investigated the effect of immune-checkpoint inhibitors (ICIs) on influenza vaccination in patients with cancer. They found that influenza vaccination is safe in these patients Some background Immune-checkpoint inhibitors (ICIs) are a new type of drug to treat cancer. ICIs can be effective in some advanced cancers,...
Read More
In a nutshell This article investigated the safety and effectiveness of BRAF inhibitors like vemurafenib (Zelboraf) and dabrafenib (Tafinlar) and immunotherapy such as ipilimumab (Yervoy) in a real-world setting for patients with advanced melanoma. The authors concluded that this therapy is safe and...
Read MoreIn a nutshell This study investigated whether body-mass index (BMI) had any effect on survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy. The study found that male metastatic melanoma patients who had a high BMI had improved survival compared to patients with normal BMI. Some background Targeted...
Read More
In a nutshell This study investigated the effectiveness of Talimogene Laherparepvec (T-VEC) combined with ipilimumab (Yervoy) and ipilimumab alone to treat patients with melanoma. Researchers suggested that the combined treatment was associated with better outcomes. Some background Newer therapies, such as immunotherapy have changed cancer...
Read MoreIn a nutshell This study investigated the effectiveness and safety of treatment with ipilimumab (Yervoy) after anti-PD1 agents such as nivolumab (Opdivo) or pembrolizumab (Keytruda). Researchers suggested that patients can benefit from treatment with ipilimumab, but at a cost of a higher toxicity. Some...
Read More
In a nutshell This study developed guidelines for the early detection and treatment of hypophysitis (HP; inflammation of the pituitary gland), a side effect of treatment with ipilimumab. Researchers suggested that these guidelines are necessary to ensure early detection and treatment of this condition to prevent associated mortality. Some background...
Read More
In a nutshell The authors analyzed the effectiveness of ipilimumab (Yervoy) combined with fotemustine (Muphoran) in advanced melanoma patients. Some background In advanced melanoma (stage III/IV), cancer spreads rapidly from the skin to other parts of the body. This is known as...
Read MoreIn a nutshell The authors analyzed the 5-year survival rate in advanced melanoma patients treated with a combination of ipilimumab (Yervoy) and dacarbazine (DTIC, DTIC-Dome) in a phase III clinical trial. Some background In advanced melanoma (stage III/IV), cancer spreads from the skin to other parts of the...
Read MoreIn a nutshell The authors reviewed immunotherapies and targeted therapies for the treatment of advanced melanoma. Some background In advanced melanoma (stage IV), cancer spreads from the skin to other parts of the body. Immunotherapy and targeted therapy are promising treatment options for this disease. These therapies...
Read More
In a nutshell The authors compared nivolumab (Opdivo) in combination with ipilimumab (Yervoy) to ipilimumab alone in the treatment of advanced melanoma. Some background In the advanced stages of melanoma (stage III/IV), cancer spreads from the skin to other parts of the body. In many melanoma...
Read More
In a nutshell The authors reviewed the biology as well as current and future treatment options for eye melanoma. Some background Uveal melanoma is a rare cancer (melanoma) of the eye. It involves three parts of the eye (iris, ciliary body and choroid) known together as the uvea. Eye melanoma is associated with a high risk...
Read More
